immunohistochemistry. Materials and methods Patients and genetic testing The Institutional Review Board of Daping Hospital of the Third Military Medical University approved this study. Written informed consents were obtained from the patients for use of
Yiqiang Huang, Lin-ang Wang, Qiubo Xie, Jian Pang, Luofu Wang, Yuting Yi, Jun Zhang, Yao Zhang, Rongrong Chen, Weihua Lan, Dianzheng Zhang and Jun Jiang
Monia Cito, Silvia Pellegrini, Lorenzo Piemonti and Valeria Sordi
double over the next decade (for review see ( 2 )). Since 1922, exogenous insulin administration has been the most important lifesaving intervention for all T1D patients; however, chronic insulin treatment is a double-edged sword since it fails to
Yongli Fu, Yaowu Sun, Jiankun Zhang and Yu Cheng
existing uncertain evidence regarding this issue using the systematic review and meta-analysis of all published literature. Methods Literature search We performed the meta-analysis following the Preferred Reporting Items for Systematic Reviews
Agnès Linglart, Martin Biosse-Duplan, Karine Briot, Catherine Chaussain, Laure Esterle, Séverine Guillaume-Czitrom, Peter Kamenicky, Jerome Nevoux, Dominique Prié, Anya Rothenbuhler, Philippe Wicart and Pol Harvengt
adolescence. Causes of phosphate wasting are mostly due to genetic defects in factors necessary for phosphate handling; for a review read (1) . They have been summarized in Table 1 . In this review, we will consider two different types of phosphate wasting
Jes Sloth Mathiesen, Jens Peter Kroustrup, Peter Vestergaard, Kirstine Stochholm, Per Løgstrup Poulsen, Åse Krogh Rasmussen, Ulla Feldt-Rasmussen, Sten Schytte, Stefano Christian Londero, Henrik Baymler Pedersen, Christoffer Holst Hahn, Bjarki Ditlev Djurhuus, Jens Bentzen, Sören Möller, Mette Gaustadnes, Maria Rossing, Finn Cilius Nielsen, Kim Brixen, Anja Lisbeth Frederiksen, Christian Godballe and the Danish Thyroid Cancer Group (DATHYRCA)
One patient RET tested subsequent to the end date of the RET cohort in December 31, 2014. To classify the 207 molecularly unclassified MTC patients, several sources were used. First, a review of available medical records ( n = 149) was
Satoshi Higuchi, Hideki Ota, Takuya Ueda, Yuta Tezuka, Kei Omata, Yoshikiyo Ono, Ryo Morimoto, Masataka Kudo, Fumitoshi Satoh and Kei Takase
. Cardiovascular manifestations of pheochromocytoma . Cardiology in Review 2017 25 215 – 222 . ( https://doi.org/10.1097/CRD.0000000000000141 ) 10.1097/CRD.0000000000000141 28786897 4 Yu R Nissen NN Bannykh SI . Cardiac complications as initial
K G Samsom, L M van Veenendaal, G D Valk, M R Vriens, M E T Tesselaar and J G van den Berg
genomic landscape of SI-NETs remains poorly elucidated and biomarkers have not yet been identified. Moreover, the genetic constitution of SI-NETs has been shown to differ compared to pancreatic NETs ( 11 ). With this review we aim to provide the clinician
Zeming Liu, Di Hu, Yihui Huang, Sichao Chen, Wen Zeng, Ling Zhou, Wei Zhou, Min Wang, Haifeng Feng, Wei Wei, Chao Zhang, Danyang Chen and Liang Guo
undertook the research, Y H H, S C C and W Z performed the analyses, Z M L and D H wrote the main manuscript text and prepared figures. All authors reviewed the manuscript. References 1 Pacini F Schlumberger M Dralle H Elisei R Smit JW Wiersinga W
Benjamin G Challis, Andrew S Powlson, Ruth T Casey, Carla Pearson, Brian Y Lam, Marcella Ma, Deborah Pitfield, Giles S H Yeo, Edmund Godfrey, Heok K Cheow, V Krishna Chatterjee, Nicholas R Carroll, Ashley Shaw, John R Buscombe and Helen L Simpson
involved in tumour development and autonomous insulin secretion. Patients and methods Study population We retrospectively reviewed medical records of patients presenting to our institution between 2003 and 2016 with a diagnosis of
Maria Cristina De Martino, R A Feelders, Claudia Pivonello, Chiara Simeoli, Fortuna Cristina Papa, Annamaria Al Colao, Rosario Pivonello and L J Hofland
Adrenocortical carcinomas (ACC) are rare tumors with scant treatment options for which new treatments are required. The mTOR pathway mediates the intracellular signals of several growth factors, including the IGFs, and therefore represents a potential attractive pathway for the treatment of several malignancies including ACCs. Several mTOR inhibitors, including sirolimus, temsirolimus and everolimus have been clinically developed.
This review summarizes the results of the studies evaluating the expression of the mTOR pathway components in ACCs, the effects of the mTOR inhibitors alone or in combination with other drugs in preclinical models of ACC and the early experience with the use of these compounds in the clinical setting.
The mTOR pathway seems a potential target for treatment of patients with ACC, but further investigation is still required to define the potential role of mTOR inhibitors alone or in combination with other drugs in the treatment of ACC patients.